Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomized study to assess safety, tolerability, and pharmacokinetics of intranasal zavegepant multiple doses in healthy fasted adults

Next Previous
Trial Profile

A double blind, randomized study to assess safety, tolerability, and pharmacokinetics of intranasal zavegepant multiple doses in healthy fasted adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zavegepant (Primary)
  • Indications Allergic asthma; COVID-19 respiratory infection; Migraine
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 27 Apr 2023 Results of pooled analysis (72 subjects (SAD: 54 active/18 placebo) and 71 subjects (MAD: 56 active/16 placebo)) assessing the cardiovascular safety of single and multiple ascending doses (SAD/MAD) of zavegepant nasal spray from two Phase 1 studies, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society
  • 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top